Drugs /

ruxolitinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
ruxolitinib
Trade Name(s):
Jakafi
NCI Definition [1]:
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Clinical Trials

View Clinical Trials for ruxolitinib

Ruxolitinib has been investigated in 64 clinical trials, of which 55 are open and 9 are closed. Of the trials investigating ruxolitinib, 17 are phase 1 (16 open), 14 are phase 1/phase 2 (11 open), 24 are phase 2 (19 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open).

KMT2A Fusion, KMT2A-AFF1 Fusion, and KMT2A-ELL Fusion are the most frequent biomarker inclusion criteria for ruxolitinib clinical trials.

Primary myelofibrosis, myelofibrosis, and myelofibrosis transformation in essential thrombocythemia are the most common diseases being investigated in ruxolitinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ruxolitinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ruxolitinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ruxolitinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
incb018424, Jakafi, oral jak inhibitor incb18424, ruxolitinib (product), incb-018424, incb424, oral jak inhibitor incb18424, ruxolitinib, (3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile, ruxolitinib, incb-18424, incb18424, oral janus-associated kinase inhibitor incb18424, ruxolitinib (substance)
Drug Categories [2]:
JAK inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
JAK1, JAK2
NCIT ID [1]:
C77888
SNOMED ID [1]:
R-FB9DE

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.